Please use this identifier to cite or link to this item:
Title: Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy.
[Sereno, Maria; Moreno Rubio, Juan; Casado, Enrique; Falagan, Sandra; Lopez-Gomez, Miriam; Merino, Maria; Gomez-Raposo, Cesar; Zambrana Tebar, Francisco] Infanta Sofia Univ Hosp, Dept Med Oncol, Madrid, Spain.
[Gutierrez-Gutierrez, Gerardo] Infanta Sofia Univ Hosp, Dept Neurol, Madrid, Spain.
[Rodriguez-Salas, Nuria] La Paz Univ Hosp, Dept Med Oncol, Madrid, Spain.
Sereno, M (reprint author), Infanta Sofia Univ Hosp, Dept Med Oncol, Madrid, Spain.
Issue Date: 2017
Citation: BMC Cancer. 2017 01;(17)1:63
Abstract: Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around 60-80% of the patients, and 15% of them develop severe neuropathy. The pathophysiology of oxaliplatin neurotoxicity remains unclear. SCN9A is a gene codifying for a subtype sodium channel (type IX, subunit α) and mutations in this gene are involved in neuropathic perception. In this study we investigated whether SCN9A genetic variants were associated with risk of neurotoxicity in patients diagnosed of cancer on treatment with oxaliplatin.
PMID: 28103821
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos
Hospitales > H. U. Infanta Sofía > Artículos
Hospitales > H. U. La Paz > Artículos

Files in This Item:
File Description SizeFormat 
PMC5248487.pdf329.92 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.